An open-label, escalating dose, proof of concept study to determine the effects of single oral doses of PSD506 on unstable urinary bladder contractions induced by volume provocation in subjects with detrusor hyper-reflexia secondary to spinal injuries above T12.
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2017
At a glance
- Drugs PSD 506 (Primary)
- Indications Overactive bladder
- Focus Proof of concept; Therapeutic Use
- Sponsors Plethora Solutions
- 09 Feb 2017 Last checked against ISRCTN: Current Controlled Trials record.
- 06 May 2011 New trial record